Koers RedHill Biopharma Ltd TEL AVIV STOCK EXCHANGE
Aandelen
IL0011223810
Farmaceutische producten
Omzet 2022 | 61,8 mln. 23,53 mld. 57,8 mln. | Omzet 2023 | 6,53 mln. 2,49 mld. 6,11 mln. | Marktkapitalisatie | 28,72 mln. 10,94 mld. 26,87 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -71 mln. -27,03 mld. -66,4 mln. | Nettowinst (verlies) 2023 | 23 mln. 8,76 mld. 21,51 mln. | EV/omzet 2022 | 1,87 x |
Nettoschuld 2022 | 103 mln. 39,1 mld. 96,06 mln. | Nettoliquiditeiten 2023 | 4,4 mln. 1,67 mld. 4,11 mln. | EV/omzet 2023 | 3,73 x |
K/w-verhouding 2022 |
-0,12
x | K/w-verhouding 2023 |
0,4
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 99% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Dror Ben-Asher
CEO | Chief Executive Officer | 59 | 03-08-09 |
Ori Shilo
FOU | Founder | 57 | 03-08-09 |
Razi Ingber
DFI | Director of Finance/CFO | - | 05-01-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Rick Scruggs
BRD | Director/Board Member | 64 | 01-01-16 |
Shmuel Cabilly
BRD | Director/Board Member | 74 | 26-08-10 |
Director/Board Member | 80 | 03-05-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-4,66% | 86,13 mld. | |
+1,32% | 39,82 mld. | |
-19,27% | 30,42 mld. | |
+57,86% | 25,23 mld. | |
-17,69% | 11,6 mld. | |
-43,00% | 11,51 mld. | |
-9,14% | 11,95 mld. | |
+5,24% | 8,71 mld. | |
-8,42% | 8,12 mld. |